Cargando…
Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy
BACKGROUND: Vitamin D (VD) is important in hepatic fibrogenesis in animal models and human studies. VD deficiency is associated with liver fibrosis progression. Metabolic dysfunction of the liver, as an intermediate organ for VD metabolism, contributes partly to this deficiency. We hypothesized that...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568415/ https://www.ncbi.nlm.nih.gov/pubmed/33069226 http://dx.doi.org/10.1186/s12876-020-01485-8 |
_version_ | 1783596514780643328 |
---|---|
author | Sriphoosanaphan, Supachaya Thanapirom, Kessarin Suksawatamnuay, Sirinporn Thaimai, Panarat Sittisomwong, Sukanya Sonsiri, Kanokwan Srisoonthorn, Nunthiya Teeratorn, Nicha Tanpowpong, Nattaporn Chaopathomkul, Bundit Treeprasertsuk, Sombat Poovorawan, Yong Komolmit, Piyawat |
author_facet | Sriphoosanaphan, Supachaya Thanapirom, Kessarin Suksawatamnuay, Sirinporn Thaimai, Panarat Sittisomwong, Sukanya Sonsiri, Kanokwan Srisoonthorn, Nunthiya Teeratorn, Nicha Tanpowpong, Nattaporn Chaopathomkul, Bundit Treeprasertsuk, Sombat Poovorawan, Yong Komolmit, Piyawat |
author_sort | Sriphoosanaphan, Supachaya |
collection | PubMed |
description | BACKGROUND: Vitamin D (VD) is important in hepatic fibrogenesis in animal models and human studies. VD deficiency is associated with liver fibrosis progression. Metabolic dysfunction of the liver, as an intermediate organ for VD metabolism, contributes partly to this deficiency. We hypothesized that improving hepatic fibrosis and inflammation in chronic hepatitis C (CHC) patients after eradication with direct-acting antivirals (DAA) would increase 25-hydroxyVD [25(OH)VD] levels. METHODS: Eighty CHC patients (17 chronic hepatitis, and 63 cirrhosis) were enrolled. Baseline characteristics, hepatitis C viral load (VL), genotypes, liver enzymes and liver stiffness measurements (LSM) were assessed at baseline. Blood samples for 25(OH)VD and the procollagen type III N-terminal peptide (P3NP) were collected at baseline, 24 and 48 weeks. LSMs were re-evaluated at 48 weeks. Serum 25(OH)VD levels < 30 ng/mL were defined as VD insufficiency/deficiency. Paired t-tests were used for statistical analyses. RESULTS: Among 80 patients, the mean age was 57.7 ± 10.5 years, and 52.5% were men. The mean VL was 6.1 ± 0.7 logIU/mL with genotype 1 predominance (55%). All patients achieved sustained virological response. The alanine aminotransferase levels decreased from 79.9 ± 53.3 U/L at baseline to 25.7 ± 17.2 and 22.3 ± 11.0 U/L at 24 and 48 weeks, respectively (p < 0.001). The mean LSM decreased from 19.2 ± 15.3 to 11.7 ± 8.0 kPa at 48 weeks (p < 0.001). The P3NP levels decreased from 43.6 ± 22.0 ng/mL before treatment to 35.7 ± 21.1 and 29.4 ± 15.0 ng/mL at 24 and 48 weeks, respectively (p < 0.001). The proportions of VD insufficiency/deficiency were 72.5%, 91.3%, and 86.5% at baseline, 24 and 48 weeks, respectively. The 25(OH)VD levels decreased from 26.3 ± 10.7 ng/mL at baseline to 20.8 ± 8.1 and 20.8 ± 8.5 ng/mL at 24 and 48 weeks, respectively (p < 0.001). CONCLUSIONS: Curative treatment with DAA attenuated the liver stiffness and inflammation but did not improve VD levels. Over 80% of patients remained VD insufficient/deficient. Whether VD replacement during and after DAA therapy can improve hepatic fibrosis remains unclear. Trial registration The Thai Clinical Trial Registry as TCTR20161025001 (31 October 2016). http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=2136. |
format | Online Article Text |
id | pubmed-7568415 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-75684152020-10-20 Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy Sriphoosanaphan, Supachaya Thanapirom, Kessarin Suksawatamnuay, Sirinporn Thaimai, Panarat Sittisomwong, Sukanya Sonsiri, Kanokwan Srisoonthorn, Nunthiya Teeratorn, Nicha Tanpowpong, Nattaporn Chaopathomkul, Bundit Treeprasertsuk, Sombat Poovorawan, Yong Komolmit, Piyawat BMC Gastroenterol Research Article BACKGROUND: Vitamin D (VD) is important in hepatic fibrogenesis in animal models and human studies. VD deficiency is associated with liver fibrosis progression. Metabolic dysfunction of the liver, as an intermediate organ for VD metabolism, contributes partly to this deficiency. We hypothesized that improving hepatic fibrosis and inflammation in chronic hepatitis C (CHC) patients after eradication with direct-acting antivirals (DAA) would increase 25-hydroxyVD [25(OH)VD] levels. METHODS: Eighty CHC patients (17 chronic hepatitis, and 63 cirrhosis) were enrolled. Baseline characteristics, hepatitis C viral load (VL), genotypes, liver enzymes and liver stiffness measurements (LSM) were assessed at baseline. Blood samples for 25(OH)VD and the procollagen type III N-terminal peptide (P3NP) were collected at baseline, 24 and 48 weeks. LSMs were re-evaluated at 48 weeks. Serum 25(OH)VD levels < 30 ng/mL were defined as VD insufficiency/deficiency. Paired t-tests were used for statistical analyses. RESULTS: Among 80 patients, the mean age was 57.7 ± 10.5 years, and 52.5% were men. The mean VL was 6.1 ± 0.7 logIU/mL with genotype 1 predominance (55%). All patients achieved sustained virological response. The alanine aminotransferase levels decreased from 79.9 ± 53.3 U/L at baseline to 25.7 ± 17.2 and 22.3 ± 11.0 U/L at 24 and 48 weeks, respectively (p < 0.001). The mean LSM decreased from 19.2 ± 15.3 to 11.7 ± 8.0 kPa at 48 weeks (p < 0.001). The P3NP levels decreased from 43.6 ± 22.0 ng/mL before treatment to 35.7 ± 21.1 and 29.4 ± 15.0 ng/mL at 24 and 48 weeks, respectively (p < 0.001). The proportions of VD insufficiency/deficiency were 72.5%, 91.3%, and 86.5% at baseline, 24 and 48 weeks, respectively. The 25(OH)VD levels decreased from 26.3 ± 10.7 ng/mL at baseline to 20.8 ± 8.1 and 20.8 ± 8.5 ng/mL at 24 and 48 weeks, respectively (p < 0.001). CONCLUSIONS: Curative treatment with DAA attenuated the liver stiffness and inflammation but did not improve VD levels. Over 80% of patients remained VD insufficient/deficient. Whether VD replacement during and after DAA therapy can improve hepatic fibrosis remains unclear. Trial registration The Thai Clinical Trial Registry as TCTR20161025001 (31 October 2016). http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=2136. BioMed Central 2020-10-17 /pmc/articles/PMC7568415/ /pubmed/33069226 http://dx.doi.org/10.1186/s12876-020-01485-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Sriphoosanaphan, Supachaya Thanapirom, Kessarin Suksawatamnuay, Sirinporn Thaimai, Panarat Sittisomwong, Sukanya Sonsiri, Kanokwan Srisoonthorn, Nunthiya Teeratorn, Nicha Tanpowpong, Nattaporn Chaopathomkul, Bundit Treeprasertsuk, Sombat Poovorawan, Yong Komolmit, Piyawat Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy |
title | Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy |
title_full | Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy |
title_fullStr | Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy |
title_full_unstemmed | Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy |
title_short | Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy |
title_sort | changes in hepatic fibrosis and vitamin d levels after viral hepatitis c eradication using direct-acting antiviral therapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568415/ https://www.ncbi.nlm.nih.gov/pubmed/33069226 http://dx.doi.org/10.1186/s12876-020-01485-8 |
work_keys_str_mv | AT sriphoosanaphansupachaya changesinhepaticfibrosisandvitamindlevelsafterviralhepatitisceradicationusingdirectactingantiviraltherapy AT thanapiromkessarin changesinhepaticfibrosisandvitamindlevelsafterviralhepatitisceradicationusingdirectactingantiviraltherapy AT suksawatamnuaysirinporn changesinhepaticfibrosisandvitamindlevelsafterviralhepatitisceradicationusingdirectactingantiviraltherapy AT thaimaipanarat changesinhepaticfibrosisandvitamindlevelsafterviralhepatitisceradicationusingdirectactingantiviraltherapy AT sittisomwongsukanya changesinhepaticfibrosisandvitamindlevelsafterviralhepatitisceradicationusingdirectactingantiviraltherapy AT sonsirikanokwan changesinhepaticfibrosisandvitamindlevelsafterviralhepatitisceradicationusingdirectactingantiviraltherapy AT srisoonthornnunthiya changesinhepaticfibrosisandvitamindlevelsafterviralhepatitisceradicationusingdirectactingantiviraltherapy AT teeratornnicha changesinhepaticfibrosisandvitamindlevelsafterviralhepatitisceradicationusingdirectactingantiviraltherapy AT tanpowpongnattaporn changesinhepaticfibrosisandvitamindlevelsafterviralhepatitisceradicationusingdirectactingantiviraltherapy AT chaopathomkulbundit changesinhepaticfibrosisandvitamindlevelsafterviralhepatitisceradicationusingdirectactingantiviraltherapy AT treeprasertsuksombat changesinhepaticfibrosisandvitamindlevelsafterviralhepatitisceradicationusingdirectactingantiviraltherapy AT poovorawanyong changesinhepaticfibrosisandvitamindlevelsafterviralhepatitisceradicationusingdirectactingantiviraltherapy AT komolmitpiyawat changesinhepaticfibrosisandvitamindlevelsafterviralhepatitisceradicationusingdirectactingantiviraltherapy |